Use of Cholecystokinin-Octapeptide for the Prevention of Parenteral Nutrition-Associated Cholestasis

To determine whether cholecystokinin-octapeptide (CCK-OP) would prevent or ameliorate parenteral nutrition-associated cholestasis (PNAC) among high-risk neonates treated with total parenteral nutrition. This was a multicenter, double-blind, randomized, controlled trial conducted between 1996 and 200...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 2005-05, Vol.115 (5), p.1332-1340
Main Authors: Teitelbaum, Daniel H, Tracy, Thomas F., Jr, Aouthmany, Moustafa M, Llanos, Adolfo, Brown, Morton B, Yu, Sunkyung, Brown, Marilyn R, Shulman, Robert J, Hirschl, Ronald B, Derusso, Patricia A, Cox, Jeanne, Dahlgren, Jacqueline, Groner, Jonathan I, Strouse, Peter J
Format: Article
Language:English
Subjects:
Babies
Bile
Bilirubin - blood
Biological and medical sciences
Care and treatment
Cholecystokinin
Cholestasis
Cholestasis - etiology
Cholestasis - prevention & control
Diagnosis
Double-Blind Method
Enterocolitis, Neonatal necrotizing
Enterocolitis, Pseudomembranous
Gallbladder - diagnostic imaging
Gastroenterology. Liver. Pancreas. Abdomen
General aspects
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases - etiology
Infant, Premature, Diseases - prevention & control
Infant, Very Low Birth Weight
Jaundice, Obstructive
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Medical sciences
Necrotizing enterocolitis
Nutrition
Other diseases. Semiology
Parenteral Nutrition, Total - adverse effects
Pediatrics
Prevention
Risk factors
Sincalide - therapeutic use
Treatment Failure
Ultrasonography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine whether cholecystokinin-octapeptide (CCK-OP) would prevent or ameliorate parenteral nutrition-associated cholestasis (PNAC) among high-risk neonates treated with total parenteral nutrition. This was a multicenter, double-blind, randomized, controlled trial conducted between 1996 and 2001. Neonates at risk for the development of PNAC included very low birth weight neonates and those with major surgical conditions involving the gastrointestinal tract. Tertiary care hospitals. Patients were randomized to receive CCK-OP (0.04 mug/kg per dose, twice daily) or placebo. Eligible infants were all
ISSN:0031-4005
1098-4275
DOI:10.1542/peds.2004-1014